A preliminary evaluation of efficacy and safety of Wharton's jelly mesenchymal stem cell transplantation in patients with type 2 diabetes mellitus

Stem Cell Research and Therapy

Volumn 5, Issue 2, 2014, Pages

  Liu, Xuebin ^a   Zheng, Pei ^a   Wang, Xiaodong ^a   Dai, Guanghui ^a   Cheng, Hongbin ^a   Zhang, Zan ^a   Hua, Rongrong ^a   Niu, Xinxin ^a   Shi, Jing ^a   An, Yihua ^a  

^a GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; FEVER; FOLLOW UP; GLUCOSE BLOOD LEVEL; HEADACHE; HEMATOMA; HUMAN; INTRAPANCREATIC ENDOVASCULAR INJECTION; LYMPHOCYTE COUNT; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PANCREAS ISLET BETA CELL; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROCEDURES CONCERNING CELLS; PROSPECTIVE STUDY; THERAPY EFFECT; YOUNG ADULT; ADVERSE EFFECTS; CELL DIFFERENTIATION; CLINICAL TRIAL; CYTOLOGY; DIABETES MELLITUS, TYPE 2; MIDDLE AGED; PHYSIOLOGY; PROCEDURES; WHARTON JELLY;

CELL DIFFERENTIATION; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MIDDLE AGED; PROSPECTIVE STUDIES; WHARTON JELLY;

EID: 84901022780     PISSN: None     EISSN: 17576512     Source Type: Journal    
DOI: 10.1186/scrt446     Document Type: Article

References (30)

1. An immune origin of type 2 diabetes? Kolb H, Mandrup-Poulsen T, Diabetologia 2005 48 1038 1050 15864529 (Pubitemid 40909636)
2. Self-assembling nanofibers inhibit glial scar formation and promote axon elongation after spinal cord injury. Tysseling-Mattiace VM, Sahni V, Niece KL, Birch D, Czeisler C, Fehlings MG, Stupp SI, Kessler JA, J Neurosci 2008 28 3814 3823 10.1523/JNEUROSCI.0143-08.2008 18385339
3. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the U.K. Prospective Diabetes Study (UKPDS 57). Wright A, Burden AC, Paisey RB, Cull CA, Holman RR, Diabetes Care 2002 25 330 336 10.2337/diacare.25.2.330 11815505 (Pubitemid 41079631)
4. Efficacy of autologous bone marrow-derived stem cell transplantation in patients with type 2 diabetes mellitus. Bhansali A, Upreti V, Khandelwal N, Marwaha N, Gupta V, Sachdeva N, Sharma RR, Saluja K, Dutta P, Walia R, Minz R, Bhadada S, Das S, Ramakrishnan S, Stem Cells Dev 2009 18 1407 1416 10.1089/scd.2009.0164 19686048
5. Transplantation of placenta-derived mesenchymal stem cells in type 2 diabetes: a pilot study. Jiang R, Han Z, Zhuo G, Qu X, Li X, Wang X, Shao Y, Yang S, Han ZC, Front Med 2011 5 94 100 10.1007/s11684-011-0116-z 21681681
6. Treatment of foot disease in patients with type 2 diabetes mellitus using human umbilical cord blood mesenchymal stem cells: response and correction of immunological anomalies. Li XY, Zheng ZH, Guo J, Zhang Y, Li H, Wang YW, Ren J, Wu ZB, Curr Pharm Des 2013 19 4893 4899 10.2174/13816128113199990326 23343120
7. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, Chen H, J Clin Invest 2003 112 1821 1830 10.1172/JCI200319451 14679177 (Pubitemid 38063705)
8. Islet inflammation impairs the pancreatic beta-cell in type 2 diabetes. Donath MY, Boni-Schnetzler M, Ellingsgaard H, Ehses JA, Physiology (Bethesda) 2009 24 325 331 10.1152/physiol.00032.2009 19996363
9. Anti-inflammation role for mesenchymal stem cells transplantation in myocardial infarction. Guo J, Lin GS, Bao CY, Hu ZM, Hu MY, Inflammation 2007 30 97 104 10.1007/s10753-007-9025-3 17497204 (Pubitemid 46985774)
10. Human umbilical cord mesenchymal stem cells reduce fibrosis of bleomycin-induced lung injury. Moodley Y, Atienza D, Manuelpillai U, Samuel CS, Tchongue J, Ilancheran S, Boyd R, Trounson A, Am J Pathol 2009 175 303 313 10.2353/ajpath.2009.080629 19497992
11. Umbilical cord mesenchymal stem cell transplantation in severe and refractory systemic lupus erythematosus. Sun L, Wang D, Liang J, Zhang H, Feng X, Wang H, Hua B, Liu B, Ye S, Hu X, Xu W, Zeng X, Hou Y, Gilkeson GS, Silver RM, Lu L, Shi S, Arthritis Rheum 2010 62 2467 2475 10.1002/art.27548 20506343
12. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Le Blanc K, Rasmusson I, Sundberg B, Gotherstrom C, Hassan M, Uzunel M, Ringden O, Lancet 2004 363 1439 1441 10.1016/S0140-6736(04)16104-7 15121408 (Pubitemid 38586721)
13. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A, Blood 2005 106 1755 1761 10.1182/blood-2005-04-1496 15905186 (Pubitemid 41208591)
14. Diagnosis and classification of diabetes mellitus. American Diabetes Association, Diabetes Care 2006 29 43 S48 16373932
15. University of Oxford: The Diabetes Trial Centre for Diabetes, Endocrinology and Metabolism. [ http://www.dtu.ox.ac.uk ]
16. Use and abuse of HOMA modeling. Wallace TM, Levy JC, Matthews DR, Diabetes Care 2004 27 1487 1495 10.2337/diacare.27.6.1487 15161807 (Pubitemid 38680001)
17. Defining the relationship between plasma glucose and HbA(1c): analysis of glucose profiles and HbA(1c) in the Diabetes Control and Complications Trial. Rohlfing CL, Wiedmeyer HM, Little RR, England JD, Tennill A, Goldstein DE, Diabetes Care 2002 25 275 278 10.2337/diacare.25.2.275 11815495 (Pubitemid 41079621)
18. Inflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam Study. Spranger J, Kroke A, Mohlig M, Hoffmann K, Bergmann MM, Ristow M, Boeing H, Pfeiffer AF, Diabetes 2003 52 812 817 10.2337/diabetes.52.3.812 12606524 (Pubitemid 36323590)
19. Inflammation, stress, and diabetes. Wellen KE, Hotamisligil GS, J Clin Invest 2005 115 1111 1119 10.1172/JCI200525102 15864338 (Pubitemid 40629025)
20. Skeletal muscle insulin resistance: role of inflammatory cytokines and reactive oxygen species. Wei Y, Chen K, Whaley-Connell AT, Stump CS, Ibdah JA, Sowers JR, Am J Physiol Regul Integr Comp Physiol 2008 294 673 R680 10.1152/ajpregu.00561.2007 18094066 (Pubitemid 351346942)
21. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G, Am J Physiol Endocrinol Metab 2001 280 745 E751 11287357
22. Is there a role for locally produced interleukin-1 in the deleterious effects of high glucose or the type 2 diabetes milieu to human pancreatic islets? Welsh N, Cnop M, Kharroubi I, Bugliani M, Lupi R, Marchetti P, Eizirik DL, Diabetes 2005 54 3238 3244 10.2337/diabetes.54.11.3238 16249450 (Pubitemid 43334380)
23. Human umbilical cord blood-derived mesenchymal stem cells improve neurological abnormalities of Niemann-Pick type C mouse by modulation of neuroinflammatory condition. Lee H, Bae JS, Jin HK, J Vet Med Sci 2010 72 709 717 10.1292/jvms.09-0495 20124762
24. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. Larsen CM, Faulenbach M, Vaag A, Volund A, Ehses JA, Seifert B, Mandrup-Poulsen T, Donath MY, N Engl J Med 2007 356 1517 1526 10.1056/NEJMoa065213 17429083 (Pubitemid 46588416)
25. Normalization of obesity-associated insulin resistance through immunotherapy. Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, Dorfman R, Wang Y, Zielenski J, Mastronardi F, Maezawa Y, Drucker DJ, Engleman E, Winer D, Dosch HM, Nat Med 2009 15 921 929 10.1038/nm.2001 19633657
26. T-lymphocyte infiltration in visceral adipose tissue: a primary event in adipose tissue inflammation and the development of obesity-mediated insulin resistance. Kintscher U, Hartge M, Hess K, Foryst-Ludwig A, Clemenz M, Wabitsch M, Fischer-Posovszky P, Barth TF, Dragun D, Skurk T, Hauner H, Bluher M, Unger T, Wolf AM, Knippschild U, Hombach V, Marx N, Arterioscler Thromb Vasc Biol 2008 28 1304 1310 10.1161/ATVBAHA.108.165100 18420999
27. Autologous nonmyeloablative hematopoietic stem cell transplantation in newly diagnosed type 1 diabetes mellitus. Voltarelli JC, Couri CE, Stracieri AB, Oliveira MC, Moraes DA, Pieroni F, Coutinho M, Malmegrim KC, Foss-Freitas MC, Simoes BP, Foss MC, Squiers E, Burt RK, JAMA 2007 297 1568 1576 10.1001/jama.297.14.1568 17426276 (Pubitemid 46588370)
28. Evidence for tissue-resident mesenchymal stem cells in human adult lung from studies of transplanted allografts. Lama VN, Smith L, Badri L, Flint A, Andrei AC, Murray S, Wang Z, Liao H, Toews GB, Krebsbach PH, Peters-Golden M, Pinsky DJ, Martinez FJ, Thannickal VJ, J Clin Invest 2007 117 989 996 10.1172/JCI29713 17347686 (Pubitemid 46556755)
29. Long term effects of the implantation of Wharton's jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus. Hu J, Yu X, Wang Z, Wang F, Wang L, Gao H, Chen Y, Zhao W, Jia Z, Yan S, Wang Y, Endocr J 2013 60 347 357 10.1507/endocrj.EJ12-0343 23154532
30. Safety and efficacy of umbilical cord mesenchymal stem cell therapy in hereditary spinocerebellar ataxia. Jin JL, Liu Z, Lu ZJ, Guan DN, Wang C, Chen ZB, Zhang J, Zhang WY, Wu JY, Xu Y, Curr Neurovasc Res 2013 10 11 20 10.2174/156720213804805936 23151076